Hemophilia is the most common of the severe bleeding disorders and if not properly
managed since early infancy can lead to chronic disease and lifelong disabilities. However …

Prophylaxis is considered optimal care for children and adults with severe haemophilia A
because of its proven ability to reduce joint and other bleeding episodes. However, a 'one …

Abstract The International Immune Tolerance Study was a multicenter, prospective,
randomized comparison of high-dose (HD; 200 IU/kg/d) and low-dose (LD; 50 IU/kg 3 …

Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors
and restore normal factor pharmacokinetics in patients with hemophilia, there is a paucity of …

Immune tolerance induction (ITI) is the only strategy proven to eradicate persistent inhibitors
in severe haemophilia A patients. Thirty years experience has shown high success rates (60 …

Over a million patients worldwide currently suffer from hemophilia and other congenital
clotting factor deficiencies. Patients affected with hemophilia A and B are treated by …

Antibody eradication is the ultimate goal of inhibitor management. The only clinically proven
strategy for achieving antigen‐specific tolerance to factor VIII is immune tolerance induction …

Children with chronic illness often require prolonged or repeated venous access. They
remain at high risk for venous catheter–related complications (high‐risk patients), which …

Given the inhibitor‐associated morbidity resulting from limited effective treatment options,
antibody eradication is the ultimate goal of inhibitor management. The only clinically proven …

The life expectancy of persons with hemophilia (PWH) has increased almost 10-fold over the
past seven decades, largely due to access to safe factor replacement products. Concomitant …